An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma

[1]  A. Alhatem,et al.  Dupilumab-associated mycosis fungoides: a cross-sectional study. , 2023, Archives of dermatological research.

[2]  A. Elsensohn,et al.  Cutaneous T‐cell lymphoma following dupilumab use: a systematic review , 2022, International journal of dermatology.

[3]  M. Maurer,et al.  Mast cells and tryptase are linked to itch and disease severity in mycosis fungoides: Results of a pilot study , 2022, Frontiers in Immunology.

[4]  A. Bursztejn,et al.  Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  H. Kim,et al.  TRPM8 agonist (cryosim‐1) gel for scalp itch: a randomised, vehicle‐controlled clinical trial , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  P. Myles,et al.  Analgesia for major laparoscopic abdominal surgery: a randomised feasibility trial using intrathecal morphine , 2022, Anaesthesia.

[7]  M. Metz,et al.  Characterization of the effects on pruritus by novel treatments for atopic dermatitis , 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[8]  Wook-Joo Lee,et al.  Cutaneous Neuroimmune Interactions of TSLP and TRPV4 Play Pivotal Roles in Dry Skin-Induced Pruritus , 2021, Frontiers in Immunology.

[9]  S. Mishra,et al.  Role of TRP ion channels in pruritus , 2021, Neuroscience Letters.

[10]  Reid H. J. Olsen,et al.  Structure, function and pharmacology of human itch GPCRs , 2021, Nature.

[11]  S. Ständer,et al.  Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open‐label extension phase , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[12]  E. Carstens,et al.  Glucosylsphingosine evokes pruritus via activation of 5‐HT2A receptor and TRPV4 in sensory neurons , 2021, British journal of pharmacology.

[13]  Langchong He,et al.  p-Phenylenediamine induces immediate contact allergy and non-histaminergic itch via MRGPRX2. , 2021, Chemico-biological interactions.

[14]  V. Julia,et al.  Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. , 2021, The Journal of allergy and clinical immunology.

[15]  E. Deeks.  Difelikefalin: First Approval , 2021, Drugs.

[16]  M. Gut,et al.  Interleukin-4 and interleukin-13 induce different metabolic profiles in microglia and macrophages that relate with divergent outcomes after spinal cord injury , 2021, Theranostics.

[17]  J. Schroeder,et al.  IL-3 in the development and function of basophils. , 2021, Seminars in immunology.

[18]  M. Gajewska,et al.  Primary cutaneous indolent B-cell lymphomas – a retrospective multicenter analysis and a review of literature , 2021, Acta oncologica.

[19]  H. Stark,et al.  TRPV1 and TRPA1 Channels Are Both Involved Downstream of Histamine-Induced Itch , 2021, Biomolecules.

[20]  A. Evers,et al.  Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[21]  Ana Helena Santos,et al.  IL-31 and IL-8 in Cutaneous T-Cell Lymphoma: Looking for Their Role in Itch , 2021, Advances in hematology.

[22]  G. Yosipovitch,et al.  A protracted, postherpetic neuralgic ulcer treated with risperidone and intranasal butorphanol , 2021, JAAD case reports.

[23]  Yong Chen,et al.  Emerging Role of Transient Receptor Potential Vanilloid 4 (TRPV4) Ion Channel in Acute and Chronic Itch , 2021, International journal of molecular sciences.

[24]  B. Chung,et al.  Activation of Transient Receptor Potential Vanilloid-3 Channels in Keratinocytes Induces Pruritus in Humans , 2021, Acta dermato-venereologica.

[25]  O. Sokumbi,et al.  Evolution of Dupilumab-Associated Cutaneous Atypical Lymphoid Infiltrates , 2021, The American Journal of dermatopathology.

[26]  Yuan Zhou,et al.  Cimifugin relieves pruritus in psoriasis by inhibiting TRPV4. , 2021, Cell calcium.

[27]  R. Willemze,et al.  Serum and cutaneous transcriptional expression levels of IL31 are minimal in cutaneous T cell lymphoma variants , 2021, Biochemistry and biophysics reports.

[28]  Jennifer Y. Zhang,et al.  Epithelia-Sensory Neuron Cross Talk Underlies Cholestatic Itch Induced by Lysophosphatidylcholine , 2021, Gastroenterology.

[29]  F. Murray-Brown.  Naltrexone for cholestatic itch: a systematic review , 2021, BMJ Supportive & Palliative Care.

[30]  R. Dummer,et al.  Cutaneous T‐cell Lymphoma , 2021, The Peripheral T‐Cell Lymphomas.

[31]  M. M. Limberg,et al.  Involvement of Neuro-Immune Interactions in Pruritus With Special Focus on Receptor Expressions , 2021, Frontiers in Medicine.

[32]  Masanari Sekine,et al.  Pruritus is common in patients with chronic liver disease and is improved by nalfurafine hydrochloride , 2021, Scientific Reports.

[33]  R. Ji,et al.  Central opioid receptors mediate morphine-induced itch and chronic itch via disinhibition. , 2020, Brain : a journal of neurology.

[34]  K. Russomanno,et al.  Acceleration of cutaneous T-cell lymphoma following dupilumab administration , 2020, JAAD case reports.

[35]  M. Polymeropoulos,et al.  Neurokinin‐1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: results from EPIONE, a randomized clinical trial , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[36]  J. Silverberg,et al.  Mycosis Fungoides Unmasked by Dupilumab Treatment in a Patient With a History of Atopic Dermatitis. , 2020, Dermatitis : contact, atopic, occupational, drug.

[37]  B. Chung,et al.  A randomized, vehicle controlled clinical trial of a synthetic TRPM8 agonist (Cryosim-1) gel for itch. , 2020, Journal of the American Academy of Dermatology.

[38]  H. Kim,et al.  Itching Caused by TRPV3 (Transient Receptor Potential Vanilloid-3) Activator Application to Skin of Burn Patients , 2020, Medicina.

[39]  N. Bragazzi,et al.  Antihistamines-refractory chronic pruritus in psoriatic patients undergoing biologics: aprepitant vs antihistamine double dosage, a real-world data , 2020, The Journal of dermatological treatment.

[40]  C. Schlapbach,et al.  Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sézary syndrome , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[41]  B. Elewski,et al.  Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial* , 2020, The British journal of dermatology.

[42]  K. Peris,et al.  Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)* , 2020, The British journal of dermatology.

[43]  Ellen J. Kim,et al.  Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab. , 2020, Cutis.

[44]  Hong Liu,et al.  Mast cells and thymic stromal lymphopoietin (TSLP) expression positively correlates with pruritus intensity in dermatitis herpetiformis , 2020, European Journal of Dermatology.

[45]  T. Buhl,et al.  Protease-Activated Receptor-2 Regulates Neuro-Epidermal Communication in Atopic Dermatitis , 2020, Frontiers in Immunology.

[46]  G. Foulke,et al.  Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma. , 2020, Cutis.

[47]  S. Kimura,et al.  Dupilumab therapy in Sézary syndrome misdiagnosed as atopic dermatitis: A case report , 2020, The Journal of dermatology.

[48]  S. Kwatra,et al.  Intranasal Butorphanol Rescue Therapy for the Treatment of Intractable Pruritus: A Case Series from the Johns Hopkins Itch Clinic. , 2020, Journal of the American Academy of Dermatology.

[49]  T. Zuberbier,et al.  Effective treatment with mepolizumab in a patient with refractory Wells syndrome , 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[50]  Mark J. Miller,et al.  A basophil-neuronal axis promotes itch , 2020, Cell.

[51]  J. Sanches,et al.  Progression of mycosis fungoides after treatment with dupilumab: A case report , 2020, Dermatologic therapy.

[52]  M. Bagot,et al.  Dupilumab Treatment in Two Patients with Cutaneous T-cell Lymphomas , 2020, Acta dermato-venereologica.

[53]  G. Yosipovitch,et al.  Use of Butorphanol as Treatment for Cholestatic Itch , 2020, Digestive Diseases and Sciences.

[54]  P. Kwon,et al.  Phase 2 Trial of a Neurokinin-1 Receptor Antagonist for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients: A Randomized Clinical Trial. , 2020, Journal of the American Academy of Dermatology.

[55]  T. Hashimoto,et al.  Mechanisms of itch in stasis dermatitis: Significant role of IL-31 from macrophages. , 2020, The Journal of investigative dermatology.

[56]  J. Silverberg,et al.  Progression of Cutaneous T-Cell Lymphoma after dupilumab: Case review of 7 patients. , 2020, Journal of the American Academy of Dermatology.

[57]  J. Silverberg,et al.  Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate-to-severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 & SOLO 2, AD ADOL, and CHRONOS. , 2020, Journal of the American Academy of Dermatology.

[58]  A. Armstrong,et al.  Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis , 2020, JAMA dermatology.

[59]  M. Lebwohl,et al.  Serlopitant for Psoriatic Pruritus: a Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial. , 2020, Journal of the American Academy of Dermatology.

[60]  F. Menzaghi,et al.  Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients , 2020, Kidney international reports.

[61]  Zhou-Feng Chen,et al.  PAR2 mediates itch via TRPV3 signaling in keratinocytes. , 2020, The Journal of investigative dermatology.

[62]  S. Schwartz,et al.  Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions , 2020, Clinical Reviews in Allergy & Immunology.

[63]  T. Billiar,et al.  TSLP protects against liver I/R injury via activation of the PI3K/Akt pathway. , 2019, JCI insight.

[64]  S. Ziegler,et al.  TSLP: from allergy to cancer , 2019, Nature Immunology.

[65]  M. Nedergaard,et al.  Astrocytes in chronic pain and itch , 2019, Nature Reviews Neuroscience.

[66]  K. Bergmann,et al.  Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab , 2019, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[67]  N. Osada,et al.  Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK1/2 activation , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[68]  Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-1714. , 2019, Blood.

[69]  P. Fallon,et al.  IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation. , 2019, The Journal of investigative dermatology.

[70]  P. Kwon,et al.  The NK1 receptor antagonist serlopitant for treatment of chronic pruritus , 2019, Expert opinion on investigational drugs.

[71]  T. Chiba,et al.  Diagnosis of Mycosis Fungoides Following Administration of Dupilumab for Misdiagnosed Atopic Dermatitis. , 2019, Acta dermato-venereologica.

[72]  M. Kishibe.  Physiological and pathological roles of kallikrein-related peptidases in the epidermis. , 2019, Journal of dermatological science.

[73]  A. Reich,et al.  NK-1 Receptor Antagonists and Pruritus: Review of Current Literature , 2019, Dermatology and Therapy.

[74]  T. Hashimoto,et al.  Pruritus in ordinary scabies: IL‐31 from macrophages induced by overexpression of thymic stromal lymphopoietin and periostin , 2019, Allergy.

[75]  D. Elston,et al.  The uses of naltrexone in dermatologic conditions. , 2019, Journal of the American Academy of Dermatology.

[76]  W. Kempf,et al.  Cutaneous lymphomas—An update 2019 , 2019, Hematological oncology.

[77]  S. Snyder,et al.  MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus , 2019, Proceedings of the National Academy of Sciences.

[78]  M. Malcangio,et al.  Cathepsin S acts via protease-activated receptor 2 to activate sensory neurons and induce itch-like behaviour , 2019, Neurobiology of pain.

[79]  T. Luger,et al.  Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo‐controlled trial , 2019, Journal of the American Academy of Dermatology.

[80]  Xinzhong Dong,et al.  Activation of Mast-Cell-Expressed Mas-Related G-Protein-Coupled Receptors Drives Non-histaminergic Itch. , 2019, Immunity.

[81]  K. Kridin,et al.  Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. , 2019, Autoimmunity reviews.

[82]  V. Nielsen,et al.  The kallikrein-like activity of Heloderma venom is inhibited by carbon monoxide , 2019, Journal of Thrombosis and Thrombolysis.

[83]  J. Gerss,et al.  Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU). , 2019, Acta dermato-venereologica.

[84]  E. Simpson,et al.  Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial , 2019, Journal of the American Academy of Dermatology.

[85]  G. Dranoff,et al.  GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation. , 2019, Immunity.

[86]  A. Murakami,et al.  The proteolytic effect of mast cell tryptase to eotaxin-1/CCL11·eotaxin-2/CCL24 and eotaxin-3/CCL26 produced by conjunctival fibroblasts , 2019, Japanese Journal of Ophthalmology.

[87]  L. Ferrer,et al.  PAR2 Pepducin-Based Suppression of Inflammation and Itch in Atopic Dermatitis Models. , 2019, The Journal of investigative dermatology.

[88]  V. Gaponenko,et al.  Novel peptide nanoparticle–biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness , 2019, The Journal of allergy and clinical immunology.

[89]  E. Lerner,et al.  Targeting PAR2 with Pepducins. , 2019, The Journal of investigative dermatology.

[90]  N. Mesinkovska,et al.  Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review , 2019, JAMA dermatology.

[91]  B. Kim,et al.  Efficacy and safety of PAC‐14028 cream – a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild‐to‐moderate atopic dermatitis: a phase IIb randomized trial† , 2019, The British journal of dermatology.

[92]  S. Tishchenko,et al.  Interleukin-17: Functional and Structural Features, Application as a Therapeutic Target , 2019, Biochemistry (Moscow).

[93]  G. Porebski,et al.  Mas-Related G Protein-Coupled Receptor-X2 (MRGPRX2) in Drug Hypersensitivity Reactions , 2018, Front. Immunol..

[94]  M. Duvic,et al.  Antibody-Based Therapies for Cutaneous T-Cell Lymphoma , 2018, American Journal of Clinical Dermatology.

[95]  M. Soligo,et al.  Nerve Growth Factor: Early Studies and Recent Clinical Trials , 2018, Current neuropharmacology.

[96]  M. Hollenberg,et al.  Itch induced by peripheral mu opioid receptors is dependent on TRPV1-expressing neurons and alleviated by channel activation , 2018, Scientific Reports.

[97]  T. Hashimoto,et al.  Modulation of Itch by Localized Skin Warming and Cooling. , 2018, Acta dermato-venereologica.

[98]  W. Zieglgänsberger.  Substance P and pain chronicity , 2018, Cell and Tissue Research.

[99]  N. Brown,et al.  Aprepitant for the Treatment of Pruritus in Sézary Syndrome: A Randomized Crossover Clinical Trial , 2018, JAMA dermatology.

[100]  M. Furue,et al.  Nemolizumab in patients with moderate‐to‐severe atopic dermatitis: Randomized, phase II, long‐term extension study , 2018, The Journal of allergy and clinical immunology.

[101]  Guoqiang Shangguan,et al.  Biological Properties and the Role of IL-25 in Disease Pathogenesis , 2018, Journal of immunology research.

[102]  L. Misery,et al.  Real‐life study of anti‐itching effects of a cream containing menthoxypropanediol, a TRPM8 agonist, in atopic dermatitis patients , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[103]  S. Mott,et al.  Health‐related quality of life in patients with cutaneous T‐cell lymphoma? , 2018, International journal of dermatology.

[104]  Yong Ho Kim,et al.  miRNA-711 Binds and Activates TRPA1 Extracellularly to Evoke Acute and Chronic Pruritus , 2018, Neuron.

[105]  A. Sobolevsky,et al.  Structure and Gating Mechanism of the Transient Receptor Potential Channel TRPV3 , 2018, Nature Structural & Molecular Biology.

[106]  M. Duvic,et al.  Inflammatory cytokines and peripheral mediators in the pathophysiology of pruritus in cutaneous T‐cell lymphoma , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[107]  I. Junttila.  Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes , 2018, Front. Immunol..

[108]  H. Tey,et al.  The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch. , 2018, The Journal of investigative dermatology.

[109]  Y. Asano,et al.  Interleukin‐25 is involved in cutaneous T‐cell lymphoma progression by establishing a T helper 2‐dominant microenvironment , 2018, The British journal of dermatology.

[110]  J. R. de Sousa,et al.  Nerve Growth Factor and Pathogenesis of Leprosy: Review and Update , 2018, Front. Immunol..

[111]  Xinzhong Dong,et al.  Peripheral and Central Mechanisms of Itch , 2018, Neuron.

[112]  Matthew B. Kerby,et al.  Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo‐controlled phase 2 clinical trial , 2018, Journal of the American Academy of Dermatology.

[113]  S. Nakae,et al.  IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity , 2018, Scientific Reports.

[114]  P. Ortiz-Romero,et al.  Aprepitant improves refractory pruritus in primary cutaneous T‐cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas , 2018, The British journal of dermatology.

[115]  V. Lisowski,et al.  Inhibitors of kallikrein‐related peptidases: An overview , 2018, Medicinal research reviews.

[116]  Rupali Gupta,et al.  Regulation of Pain and Itch by TRP Channels , 2018, Neuroscience Bulletin.

[117]  Y. Asano,et al.  Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and Sézary syndrome , 2018, The Journal of dermatology.

[118]  V. Mathur,et al.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus , 2017, American Journal of Nephrology.

[119]  D. McKemy,et al.  Cooling Relief of Acute and Chronic Itch Requires TRPM8 Channels and Neurons. , 2017, The Journal of investigative dermatology.

[120]  M. Kolacz,et al.  Perioperative analgesia after intrathecal fentanyl and morphine or morphine alone for cesarean section , 2017, Medicine.

[121]  Yuetsu Tanaka,et al.  The CC chemokine ligand (CCL) 1, upregulated by the viral transactivator Tax, can be downregulated by minocycline: possible implications for long-term treatment of HTLV-1-associated myelopathy/tropical spastic paraparesis , 2017, Virology Journal.

[122]  E. Healy,et al.  Persistent kallikrein 5 activation induces atopic dermatitis‐like skin architecture independent of PAR2 activity , 2017, The Journal of allergy and clinical immunology.

[123]  Hongzhen Hu,et al.  Sensory TRP channels contribute differentially to skin inflammation and persistent itch , 2017, Nature Communications.

[124]  S. Kwatra,et al.  Aprepitant for the Treatment of Chronic Refractory Pruritus , 2017, BioMed research international.

[125]  T. Muramatsu,et al.  Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double‐blind trial , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

[126]  Y. Kuraishi,et al.  Involvement of Leukotriene B4 Released from Keratinocytes in Itch-associated Response to Intradermal Interleukin-31 in Mice. , 2017, Acta dermato-venereologica.

[127]  Hongzhen Hu,et al.  Transient receptor potential vanilloid 4–expressing macrophages and keratinocytes contribute differentially to allergic and nonallergic chronic itch , 2017, The Journal of allergy and clinical immunology.

[128]  T. Nagano,et al.  Aprepitant for refractory nivolumab-induced pruritus. , 2017, Lung cancer.

[129]  S. Ständer,et al.  Novel TRPM8 agonist cooling compound against chronic itch: results from a randomized, double‐blind, controlled, pilot study in dry skin , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[130]  P. Jagodziński,et al.  Opioid Receptors in Psoriatic Skin: Relationship with Itch. , 2017, Acta dermato-venereologica.

[131]  Ling Meng,et al.  Tryptase inhibitors: a patent review , 2017, Expert opinion on therapeutic patents.

[132]  Jonathan R. Brestoff,et al.  Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch , 2017, Cell.

[133]  B. Eiz-Vesper,et al.  Human basophils are a source of ‐ and are differentially activated by ‐ IL‐31 , 2017, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[134]  T. Kupper,et al.  Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature , 2017, BMC Cancer.

[135]  C. Pincelli.  p75 Neurotrophin Receptor in the Skin: Beyond Its Neurotrophic Function , 2017, Front. Med..

[136]  J. Breed,et al.  Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2. , 2017, Journal of molecular biology.

[137]  T. Zuberbier,et al.  Skin provocation tests may help to diagnose atopic dermatitis , 2016, Allergy.

[138]  A. Huber,et al.  An emerging role for eotaxins in neurodegenerative disease. , 2016, Clinical immunology.

[139]  D. Fairlie,et al.  Antagonism of the proinflammatory and pronociceptive actions of canonical and biased agonists of protease‐activated receptor‐2 , 2016, British journal of pharmacology.

[140]  S. Hirakawa,et al.  Vascular endothelial growth factor partially induces pruritus via epidermal hyperinnervation in imiquimod-induced psoriasiform dermatitis in mice. , 2016, Journal of dermatological science.

[141]  P. Kruzliak,et al.  Role of substance P in the cardiovascular system , 2016, Neuropeptides.

[142]  M. Maurer,et al.  Increased angiogenesis and VEGF expression correlates with disease severity in prurigo patients , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[143]  Wei Cheng,et al.  Facilitation of TRPV4 by TRPV1 is required for itch transmission in some sensory neuron populations , 2016, Science Signaling.

[144]  R. Dana,et al.  Neuropeptide substance P and the immune response , 2016, Cellular and Molecular Life Sciences.

[145]  Jungsoo Lee,et al.  Clinical Efficacy and Safety of Naltrexone Combination Therapy in Older Patients with Severe Pruritus , 2016, Annals of dermatology.

[146]  J. Guitart,et al.  Cutaneous T-cell Lymphoma and Pruritus: The Expression of IL-31 and its Receptors in the Skin. , 2016, Acta dermato-venereologica.

[147]  E. Kontny,et al.  Expression of vascular endothelial growth factor and other cytokines in atopic dermatitis, and correlation with clinical features , 2016, International journal of dermatology.

[148]  M. Tani,et al.  Eotaxin-3 (CCL26) Expression in Human Pancreatic Myofibroblasts , 2016, Pancreas.

[149]  M. Nagamine,et al.  Involvement of TRPV4 in serotonin-evoked scratching , 2015, The Journal of investigative dermatology.

[150]  H. Hermanns.  Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology. , 2015, Cytokine & growth factor reviews.

[151]  Y. Kuraishi,et al.  Increase in pruritogenic kallikrein 5 in the skin of NC mice with chronic dermatitis , 2015, Experimental dermatology.

[152]  Y. Liu,et al.  Tryptase and protease-activated receptor-2 stimulate scratching behavior in a murine model of ovalbumin-induced atopic-like dermatitis. , 2015, International immunopharmacology.

[153]  M. Furue,et al.  Mutual upregulation of endothelin‐1 and IL‐25 in atopic dermatitis , 2015, Allergy.

[154]  E. Magen,et al.  Plasma endothelin-1 levels during exacerbation of atopic dermatitis. , 2015, Allergy and asthma proceedings.

[155]  B. Boyce,et al.  Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. , 2015, Acta dermato-venereologica.

[156]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[157]  H. Watarai,et al.  Interleukin-17B Antagonizes Interleukin-25-Mediated Mucosal Inflammation. , 2015, Immunity.

[158]  A. Hawi,et al.  Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus , 2015, BMC Nephrology.

[159]  A. Khosravi,et al.  Role of IL-25 in Immunity. , 2015, Journal of clinical and diagnostic research : JCDR.

[160]  M. Sokołowska-Wojdyło,et al.  Il-31 does not correlate to pruritus related to early stage cutaneous T-cell lymphomas but is involved in pathogenesis of the disease. , 2015, Acta dermato-venereologica.

[161]  T. Kupper,et al.  CCR4 + T cell recruitment to the skin in mycosis fungoides: potential contributions by thymic stromal lymphopoietin and interleukin-16 , 2015, Leukemia & lymphoma.

[162]  A. Luster,et al.  The chemokine system in innate immunity. , 2015, Cold Spring Harbor perspectives in biology.

[163]  M. Maurer,et al.  Substance P is upregulated in the serum of patients with chronic spontaneous urticaria. , 2014, The Journal of investigative dermatology.

[164]  N. Upton,et al.  Neurokinin‐1 receptor antagonist orvepitant is an effective inhibitor of itch‐associated response in a Mongolian gerbil model of scratching behaviour , 2014, Experimental dermatology.

[165]  Xinzhong Dong,et al.  Identification of a mast cell specific receptor crucial for pseudo-allergic drug reactions , 2014, Nature.

[166]  N. Alenina,et al.  Mas and Its Related G Protein–Coupled Receptors, Mrgprs , 2014, Pharmacological Reviews.

[167]  M. Casanova,et al.  Paraneoplastic pruritus presenting with Hodgkin’s lymphoma: a case report , 2014, Journal of Medical Case Reports.

[168]  R. Dummer,et al.  Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[169]  T. Buhl,et al.  Neural peptidase endothelin-converting enzyme 1 regulates endothelin 1-induced pruritus. , 2014, The Journal of clinical investigation.

[170]  Jie Tan,et al.  Continous Epidural Butorphanol Decreases the Incidence of Intrathecal Morphine-Related Pruritus After Cesarean Section: A Randomized, Double-Blinded, Placebo-Controlled Trial , 2014, Cell Biochemistry and Biophysics.

[171]  Alain Hovnanian,et al.  Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome , 2014, The Journal of experimental medicine.

[172]  D. Polley,et al.  Biased signalling and proteinase‐activated receptors (PARs): targeting inflammatory disease , 2014, British journal of pharmacology.

[173]  S. Horwitz,et al.  Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. , 2014, Journal of the American Academy of Dermatology.

[174]  G. Yosipovitch,et al.  IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus. , 2013, The Journal of investigative dermatology.

[175]  W. Busse,et al.  Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. , 2013, The Journal of allergy and clinical immunology.

[176]  E. Carstens,et al.  Neural processing of itch , 2013, Neuroscience.

[177]  W. Silny,et al.  Neurogenic markers of the inflammatory process in atopic dermatitis: relation to the severity and pruritus , 2013, Postepy dermatologii i alergologii.

[178]  S. Jordt,et al.  TRPA1 controls inflammation and pruritogen responses in allergic contact dermatitis , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[179]  M. Kido,et al.  CCL-1 in the spinal cord contributes to neuropathic pain induced by nerve injury , 2013, Cell Death and Disease.

[180]  Christina S Gamba,et al.  The use of aprepitant in brachioradial pruritus. , 2013, JAMA dermatology.

[181]  S. Bevan,et al.  Superoxide generation and leukocyte accumulation: key elements in the mediation of leukotriene B4‐induced itch by transient receptor potential ankyrin 1 and transient receptor potential vanilloid 1 , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[182]  M. Maurer,et al.  Effective control of recalcitrant pruritus by bevacizumab: a possible role for vascular endothelial growth factor in chronic itch? , 2013, Acta dermato-venereologica.

[183]  Y. Tada,et al.  Association of nerve growth factor, chemokine (C-C motif) ligands and immunoglobulin E with pruritus in cutaneous T-cell lymphoma. , 2013, Acta dermato-venereologica.

[184]  E. Olsen,et al.  Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma. , 2012, Journal of the American Academy of Dermatology.

[185]  B. Vincenzi,et al.  Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. , 2012, The Lancet. Oncology.

[186]  Jung Hyun Han,et al.  Topical TRPM8 agonist (icilin) relieved vulva pruritus originating from lichen sclerosus et atrophicus. , 2012, Acta dermato-venereologica.

[187]  J. Wallengren.  Topical aprepitant in clinical and experimental pruritus. , 2012, Archives of dermatology.

[188]  M. Duvic,et al.  Prevalence and severity of pruritus in cutaneous T cell lymphoma , 2012, International journal of dermatology.

[189]  K. Yasui,et al.  TRPV3 as a therapeutic target for itch. , 2012, The Journal of investigative dermatology.

[190]  Q. H. Tran,et al.  Intravenous butorphanol administration reduces intrathecal morphine-induced pruritus after cesarean delivery: a randomized, double-blind, placebo-controlled study , 2012, Journal of Anesthesia.

[191]  Y. Tada,et al.  Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma. , 2012, Acta dermato-venereologica.

[192]  Kyung‐Min Lim,et al.  Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases , 2012, Archives of pharmacal research.

[193]  Ruoyu Li,et al.  Exome sequencing reveals mutations in TRPV3 as a cause of Olmsted syndrome. , 2012, American journal of human genetics.

[194]  S. E. Ross.  Pain and itch: insights into the neural circuits of aversive somatosensation in health and disease , 2011, Current Opinion in Neurobiology.

[195]  I. Dekio,et al.  Content of Vascular Endothelial Growth Factor in Stratum Corneum Well Correlates to Local Severity of Acute Inflammation in Patients with Atopic Dermatitis , 2011, International Archives of Allergy and Immunology.

[196]  M. Sugaya,et al.  Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis. , 2011, Journal of dermatological science.

[197]  E. Theodorsson,et al.  Expression of tachykinins and their receptors in plaque psoriasis with pruritus , 2011, The British journal of dermatology.

[198]  J. Utikal,et al.  Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T‐cell lymphoma , 2011, The British journal of dermatology.

[199]  S. Ryser,et al.  PAR2 absence completely rescues inflammation and ichthyosis caused by altered CAP1/Prss8 expression in mouse skin , 2011, Nature communications.

[200]  T. Luger,et al.  Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. , 2010, Journal of the American Academy of Dermatology.

[201]  Shinichi Sato,et al.  Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma. , 2010, The Journal of investigative dermatology.

[202]  T. Luger,et al.  Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy , 2010, PloS one.

[203]  T. Luger,et al.  Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis. , 2010, Journal of dermatological science.

[204]  P. Brousset,et al.  mu-Opioid receptor is induced by IL-13 within lymph nodes from patients with Sézary syndrome. , 2010, The Journal of investigative dermatology.

[205]  T. Muramatsu,et al.  Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[206]  H. Watarai,et al.  Regulation of IL-9 expression by IL-25 signaling , 2010, Nature Immunology.

[207]  R. Geha,et al.  Thymic stromal lymphopoietin , 2010, Annals of the New York Academy of Sciences.

[208]  David J. Anderson,et al.  Sensory Neuron-Specific GPCR Mrgprs Are Itch Receptors Mediating Chloroquine-Induced Pruritus , 2009, Cell.

[209]  K. Takatsu,et al.  IL-5- and eosinophil-mediated inflammation: from discovery to therapy. , 2009, International immunology.

[210]  G. Joshi,et al.  Role of intravenous naloxone in severe pruritus of acute cholestasis , 2009, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[211]  M. Sugaya,et al.  Increased serum thymic stromal lymphopoietin levels in patients with cutaneous T cell lymphoma , 2009, Clinical and experimental dermatology.

[212]  S. Devesa,et al.  Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. , 2009, Blood.

[213]  R. Watanabe,et al.  Increased CCL1 levels in the sera and blister fluid of patients with bullous pemphigoid. , 2009, Journal of dermatological science.

[214]  P. Carmeliet,et al.  Role and therapeutic potential of VEGF in the nervous system. , 2009, Physiological reviews.

[215]  G. Baliva,et al.  Quality of life and psychological distress in patients with cutaneous lymphoma. , 2009 .

[216]  Minoru Suzuki,et al.  Impact of the Gly573Ser substitution in TRPV3 on the development of allergic and pruritic dermatitis in mice. , 2009, The Journal of investigative dermatology.

[217]  T. I. Lund Nilsen,et al.  Incidence of primary cutaneous T‐cell lymphoma in Norway , 2009, The British journal of dermatology.

[218]  K. Takatsu,et al.  IL-5 and eosinophilia. , 2008, Current opinion in immunology.

[219]  Manfred Schmitt,et al.  Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7 , 2008, Biological chemistry.

[220]  E. Diamandis,et al.  Distribution of 15 human kallikreins in tissues and biological fluids. , 2007, Clinical chemistry.

[221]  H. Stammer,et al.  Treatment of pruritus with topically applied opiate receptor antagonist. , 2007, Journal of the American Academy of Dermatology.

[222]  E. Diamandis,et al.  Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients , 2007, Experimental dermatology.

[223]  S.E. Chang,et al.  Neuropeptides and their receptors in psoriatic skin in relation to pruritus , 2007, The British journal of dermatology.

[224]  D. McQueen,et al.  Endothelin‐1 activates ETA receptors to cause reflex scratching in BALB/c mice , 2007, British journal of pharmacology.

[225]  S. Gan,et al.  Significant impact of cutaneous T‐cell lymphoma on patients' quality of life , 2006, Cancer.

[226]  T. Kawakami,et al.  Oral antihistamine therapy influences plasma tryptase levels in adult atopic dermatitis. , 2006, Journal of dermatological science.

[227]  G. Caughey.  Tryptase genetics and anaphylaxis. , 2006, The Journal of allergy and clinical immunology.

[228]  Y. Maezawa,et al.  Interleukin 25 in Allergic Airway Inflammation , 2006, International Archives of Allergy and Immunology.

[229]  O. Johansson,et al.  Increased nerve growth factor and its receptors in atopic dermatitis: an immunohistochemical study , 2006, Archives of Dermatological Research.

[230]  G. Yosipovitch,et al.  Butorphanol for treatment of intractable pruritus. , 2006, Journal of the American Academy of Dermatology.

[231]  E. Morita,et al.  Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis , 2006, Archives of Dermatological Research.

[232]  A. Skoff,et al.  Nerve growth factor regulates substance P in adult sensory neurons through both TrkA and p75 receptors , 2006, Experimental Neurology.

[233]  H. Nojima,et al.  Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice. , 2006, European journal of pharmacology.

[234]  Y. Ueno,et al.  Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. , 2005, Journal of the American Society of Nephrology : JASN.

[235]  A. Keegan,et al.  Interleukin-4 (IL-4) Pathway , 2005, Science's STKE.

[236]  J. Holden,et al.  The endogenous opioid system and clinical pain management. , 2005, AACN clinical issues.

[237]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[238]  M. Dugas,et al.  Baseline serum levels of mast cell tryptase are raised in hemodialysis patients and associated with severity of pruritus , 2005, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[239]  H. Zentgraf,et al.  CCL1-CCR8 Interactions: An Axis Mediating the Recruitment of T Cells and Langerhans-Type Dendritic Cells to Sites of Atopic Skin Inflammation1 , 2005, The Journal of Immunology.

[240]  Craig Montell,et al.  The TRP Superfamily of Cation Channels , 2005, Science's STKE.

[241]  T. Luger,et al.  Antipruritische Therapie mit dem oralen Opiatrezeptorantagonisten Naltrexon , 2004, Der Hautarzt.

[242]  Bart Landuyt,et al.  Vascular Endothelial Growth Factor and Angiogenesis , 2004, Pharmacological Reviews.

[243]  P. Kam,et al.  Mast cell tryptase: a review of its physiology and clinical significance , 2004, Anaesthesia.

[244]  Lisa M. Ebert,et al.  A Skin-selective Homing Mechanism for Human Immune Surveillance T Cells , 2004, Journal of Experimental Medicine.

[245]  N. Bunnett,et al.  Protease-activated receptors: contribution to physiology and disease. , 2004, Physiological reviews.

[246]  M. Morohashi,et al.  Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch‐associated cutaneous factors , 2003, The British journal of dermatology.

[247]  E. Goldin,et al.  Topical capsaicin—a novel and effective treatment for idiopathic intractable pruritus ani: a randomised, placebo controlled, crossover study , 2003, Gut.

[248]  Thomas A. Luger,et al.  Proteinase-Activated Receptor-2 Mediates Itch: A Novel Pathway for Pruritus in Human Skin , 2003, The Journal of Neuroscience.

[249]  E. Papadavid,et al.  The relevance of peripheral blood T‐helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome , 2003, The British journal of dermatology.

[250]  T. Makino,et al.  Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis , 2002 .

[251]  D. Banville,et al.  Proenkephalin A gene products activate a new family of sensory neuron–specific GPCRs , 2002, Nature Neuroscience.

[252]  O. Johansson,et al.  Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin – an exploration of the cause of neurohyperplasia , 2002, Archives of Dermatological Research.

[253]  Luting Xu,et al.  Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. , 2001, The Journal of investigative dermatology.

[254]  M. Steinhoff,et al.  Proteinase‐activated receptor‐2 in human skin: tissue distribution and activation of keratinocytes by mast cell tryptase , 1999, Experimental dermatology.

[255]  J. Sullivan,et al.  Naltrexone: A case report of pruritus from an antipruritic , 1997, The Australasian journal of dermatology.

[256]  E. Crosby,et al.  Treatment of intrathecal morphine-induced pruritus following Caesarean section , 1997 .

[257]  M. Hollenberg,et al.  Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[258]  D. Alling,et al.  Effects of Naloxone Infusions in Patients with the Pruritus of Cholestasis: A Double-Blind, Randomized, Controlled Trial , 1995, Annals of Internal Medicine.

[259]  G. Krueger,et al.  A double-blind evaluation of topical capsaicin in pruritic psoriasis. , 1993, Journal of the American Academy of Dermatology.

[260]  T. Ebendal.  Function and evolution in the NGF family and its receptors , 1992, Journal of neuroscience research.

[261]  A. Rook,et al.  Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. , 1992, The Journal of investigative dermatology.

[262]  A. Levine,et al.  Disulfide assignments in recombinant mouse and human interleukin 4. , 1991, Biochemistry.

[263]  S. Seidenari,et al.  Neuropeptides in skin from patients with atopic dermatitis: an immunohistochemical study , 1990, The British journal of dermatology.

[264]  E. Monroe.  Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. , 1989, Journal of the American Academy of Dermatology.

[265]  H. S. Earl,et al.  Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. , 1987, The New England journal of medicine.

[266]  J. Silverberg,et al.  Phase 2b Randomized Study of Nemolizumab in Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus. , 2019, The Journal of allergy and clinical immunology.

[267]  M. Tominaga,et al.  The molecular and cellular mechanisms of itch and the involvement of TRP channels in the peripheral sensory nervous system and skin. , 2017, Allergology international : official journal of the Japanese Society of Allergology.

[268]  C. Woolf,et al.  Substance P activates Mas‐related G protein–coupled receptors to induce itch , 2017, The Journal of allergy and clinical immunology.

[269]  Yoon Seok Yang,et al.  Increased expression of three types of transient receptor potential channels (TRPA1, TRPV4 and TRPV3) in burn scars with post-burn pruritus. , 2015, Acta dermato-venereologica.

[270]  C. Curiel-Lewandrowski,et al.  Absence of full-length neurokinin-1 receptor protein expression by cutaneous T cells: implications for substance P-mediated signaling in mycosis fungoides. , 2015, Acta dermato-venereologica.

[271]  S. Whittaker,et al.  Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma. , 2013, Journal of pain and symptom management.

[272]  T. Pusl,et al.  Pathogenesis and Treatment of Pruritus in Cholestasis , 2012, Drugs.

[273]  T. Torres,et al.  Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues. , 2012, Journal of the American Academy of Dermatology.

[274]  L. Misery,et al.  Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat. , 2010, Acta dermato-venereologica.

[275]  Jung-Bum Lee,et al.  Involvement of Tryptase and Proteinase-Activated Receptor-2 in Spontaneous Itch-Associated Response in Mice With Atopy-like Dermatitis. , 2009, Journal of pharmacological sciences.

[276]  M. Steinhoff,et al.  Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases. , 2008, The Journal of investigative dermatology.

[277]  C. Montell,et al.  TRP channels. , 2007, Annual review of biochemistry.

[278]  M. Minami,et al.  Molecular pharmacology of the opioid receptors. , 1995, Pharmacology & therapeutics.

[279]  S. Ferreira,et al.  Endothelin‐1 Participation in Overt and Inflammatory Pain , 1989, Journal of cardiovascular pharmacology.